HBM Biopharma Summit 2026

27th - 29th September 2026

Park Hyatt Zurich
Registration

WELCOME

For more than a decade, HBM hosted yearly summits, providing a meeting platform for industry professionals and investors to exchange views with experts and peers about the latest developments in the biopharma industry. After the highly successful HBM Biopharma Summit 2025 we are delighted to announce the dates for the


HBM BIOPHARMA SUMMIT 2026


DATE & PLACE

27th - 29th September 2026

Park Hyatt Hotel Zurich, Switzerland


SPEAKERS

Jeffrey Berkowitz, Real Endpoints | Meenakshi Datta, Sidley Austin | Marc de Garidel, Abivax | Simon Dowker, SK Capital Partners | Richard Girling, Centerview Partners |Mathai Mammen, Parabilis Medicines | Mark C. McKenna, Mirador Therapeutics | Giovanni Mariggi, Medicxi | Dezső Mártha, Swixx BioPharma | Moncef Slaoui, Curevo Vaccine | Stuart Swanson, Swixx BioPharma | Stephen J. Ubl, PhRMA

PRINTABLE PROGRAM WITH LIST OF PARTICIPANTS

List of participants PDF download


PRESENTING COMPANIES

Abivax | Adarx | ALX | Biohaven | CellCentric | Coherus Oncology | Corxel | Cstone Pharmaceuticals | Curevo Vaccine | Denali | Dren Bio | Fangzhou | Fore Bio | Karius | Monte Rosa Therapeutics | Numab | Nuvation Bio | Parabilis | Perspective | SOBI | Swixx BioPharma | Vicore Pharma | Zymeworks


NETWORKING

With networking being a key element of this event, we look forward to inspiring discussions and a lively exchange of views among all participants.

ACCOMMODATION

The Park Hyatt hotel offers a limited number of rooms during the conference at a reduced rate. These rooms are likely to sell your soon. Please book your room at the Park Hyatt Conference Booking Site

Other nearby hotels inlcude Hotel Motel 1, Baur au Lac, Hotel Alden Splügenschloss


DRESS CODE

Business casual (casual for dinners) throughout the conference.

CONFERENCE PROGRAM

REGISTRATION & WELCOME DESK

Ballroom Foyer

INFORMAL LUNCH AT PARK HYATT HOTEL

Mezzanine Foyer

UETLIBERG - ZURICH'S VERY OWN MOUNTAIN

At 871 metres (2,858 feet) above sea level, the Uetliberg towers over Zurich's rooftops. The Uetliberg Railway takes us almost to the top, leaving only a seven-minute walk through the forest to reach the summit and the Hotel Uto Kulm. From here, you can enjoy a fascinating 360° view. The hotel's own observation tower is the best viewing point. Enjoy a light apéritif while taking in the magnificent panoramic view of the city, the lake and the Alps.

LINDT CHOCO DELUXE PRIVATE TOUR

During this 90-minute guided tour, you will gain an insight into the production of cocoa and chocolate. You will learn how the Mayan 'cult' drink evolved into a European luxury and ultimately became accessible to all. In addition to the tasting stations in the exhibition and the tasting of creamy melting Lindor creations with a Maître Chocolatier, we are also offered the exclusive opportunity to taste ingredients and preliminary products of chocolate production. Finally, you can explore the world of chocolate in the 500 m² Lindt Chocolate Shop, where you will find the finest Swiss chocolate from Lindt, as well as a variety of sweet gift ideas.

TRANSFER TO DINNER LOCATION

Meet in Lobby

INFORMAL DINNER AT RESTAURANT SEEROSE

Restaurant Seerose

Seestrasse 493
8038 Zürich

SHUTTLE SERVICE TO PARK HYATT HOTEL EVERY 30 MINUTES

Speakers

Jeffrey Berkowitz

CEO, Real Endpoints

Jeff Berkowitz is one of the rare executives whose career has spanned most key verticals in the global healthcare supply chain with executive committee and other senior roles at UnitedHealth Group, Walgreens Boots Alliance and Merck. Jeff is currently the CEO of Real Endpoints, a leader in providing insights, support and tools to strengthen access to pharmaceutical and digital health innovation for an evolving healthcare landscape with a concentrated focus on value based arrangements, patient services and market access support for biopharma manufacturers and payors. Jeff is also a Senior Advisor to the private equity firm Permira and serves as Chairman of Valeris, a portfolio company focused on patient support services. Prior to Real Endpoints, Jeff served as an Executive Vice President of UnitedHealth Group/Optum where he led Optum’s London-based International division, as CEO while also driving key strategic initiatives within Optum’s pharmacy benefits management division, OptumRx. Prior to joining UnitedHealth Group/Optum, Jeff was a member of the Executive Committee of the Walgreens Boots Alliance where he served as President of Pharma and Global Market Access. In this role, Berkowitz was responsible for generic and branded procurement, inventory management, relationships with pharmaceutical companies as well as the companies pricing and reimbursement strategies with all payors and payor segments. Jeff also led Walgreens specialty pharmacy business with over $10 billion in revenue and 5,800 employees. Before the formation of the Walgreens Boots Alliance, Jeff served as President of Walgreens Boots Alliance Development GmbH, where he was based in Bern, Switzerland for three years, with responsibility for the creation and development of a new joint venture company overseeing relationships with branded and generic pharmaceutical manufacturers. As the senior-most Walgreens executive residing outside of the U.S., Berkowitz led the global health and wellbeing efforts on the ground overseas. Prior to that, Berkowitz served as Walgreens Senior Vice President, Pharmaceutical Development and Market Access and was responsible for all pharmaceutical procurement, inventory management, managed care sales, network contracting and reimbursement. Before joining Walgreens in 2010, Jeff was senior vice president of global market access for Merck & Company, Inc. where he was accountable for all activity related to access, pricing, payer marketing, health outcomes and health technology assessments worldwide and a member of the Global Human Health and Emerging Markets leadership teams. From 2002 to 2009, Berkowitz held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. His tenure there culminated in his role as group vice president of diversified products and global market access. In this capacity, he held global P&L responsibility for the company’s $2.5 billion diversified products franchises and was a member of the global management team. As a trained lawyer who practiced for a decade, he also served as legal director for Schering-Plough’s managed care and commercial group from 1998 to 2002. Before joining Schering-Plough, Berkowitz was a health care attorney for the international law firm Proskauer LLP in New York and Washington, D.C. Berkowitz serves on the board of directors of several publicly traded healthcare companies including Lundbeck A/S and Zealand Pharmaceuticals. He also served as the Chairman of privately held PharmaTwoB and as a Board Member of the privately held prescription digital therapeutics company, Click Therapeutics. Berkowitz previously served on the Board of Directors of the Swiss-American Chamber of Commerce, Infinity Pharmaceuticals, Uniphar and Esperion. He has been recognized three times in the Top 100 Most Inspiring in the Life Sciences by PharmaVoice Magazine and serves on the Editorial Advisory Boards of Life Science Leader and Pharmaceutical Commerce magazines.

Meenakshi Datta

Sidley Austin LLP, Partner, Healthcare, Crisis Management and Strategic Response, Privacy and Cybersecurity

Meena Datta is global co-leader of the Sidley’s Healthcare practice and a member of the global Life Sciences team. She manages key strategic matters for life sciences and healthcare companies throughout the world, particularly drug pricing and market access and patient access strategy in the MFN policy landscape. She was a key lawyer on the Sidley team that defeated MFN 1 on behalf of BIO. California Life Scis. Assn. v. CMS, 2020 WL 7696050 (N.D. Cal. 2020). Clients value Meena for her problem-solving and creativity while giving measured guidance to appropriately manage and reduce risk.

Marc de Garidel

CEO, Abivax

Marc de Garidel is a recognized biotech entrepreneur and global pharmaceutical executive with a distinguished track record of building and scaling innovative healthcare companies, advancing breakthrough therapies, and creating substantial shareholder value across the biotechnology sector. Since May 2023, Marc has served as Chief Executive Officer of Abivax, leading the development of obefazimod for ulcerative colitis and driving exceptional corporate growth, from a $500M to up to $14B company in over 3 years. Prior to Abivax, he was Chief Executive Officer of CinCor Pharma from 2020 to 2023, where he successfully led the company through its acquisition by AstraZeneca. CinCor’s lead therapy was subsequently approved by the FDA as a first-in-class treatment for resistant hypertension. From 2018 to 2020, Marc served as CEO of Corvidia Therapeutics, overseeing its strategic growth and successful acquisition by Novo Nordisk. Earlier in his career, he served as Chief Executive Officer of Ipsen from 2010 to 2016, where he transformed the company into a leading global oncology player through the expansion of Somatuline and the landmark ex-U.S. licensing agreement for Cabometyx. Marc began his career at Eli Lilly and Company before spending 15 years at Amgen in senior international leadership roles. He has also served as Chairman of Ipsen since late 2010. He holds a Civil Engineering degree from ESTP Paris, a Master’s in International Management from Thunderbird School of Global Management, and an Executive MBA from Harvard Business School.

Simon Dowker

Managing Director, SK Capital Partners

Managing Director at SK Capital Partners. Previously Managing Director at PJT Partners, UBS and Jefferies, focused on global Life Sciences and Speciality Materials sectors. Board Member of Ecopol

Richard Girling

Partner, Centerview Partners

Mr. Girling established the European business of Centerview Partners in London in 2009 and co-founded the Life Sciences practice. The Centerview Partners Healthcare team has advised on a number of significant transactions including: AstraZeneca on the $119bn defence from Pfizer, Walgreens Boots Alliance on the $6.5bn sale of its Alliance Healthcare businesses to AmerisourceBergen, Teva on its TL1A partnership transaction with Sanofi, CSL on its acquisition of Aventis Behring and its acquisition of Novartis’ influenza vaccines business, Hikma on its acquisition of Boehringer Ingelheim’s Roxane Laboratories, Galenica on its $2bn IPO of Galenica Santé and separation of Vifor Pharma, Sanofi on its $1.9bn acquisition of Kadmon and up to $1.1bn sale of Enjaymo to Recordati, Takeda on its acquisition of TiGenix and Arvelle Therapeutics on its $960mm sale to Angelini Pharma. Recently Mr. Girling has advised Zealand Pharma on its up to $5.3bn collaboration and licensing agreement with Roche, EsoBiotec on its up to $1bn sale to AstraZeneca and WBA on its $23.7bn sale to Sycamore Partners. Mr. Girling established Merrill Lynch’s European healthcare practice in 1998, and was Global Co Head of Healthcare investment banking for the last six of those years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization. Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling is an Honorary Fellow of St Anne‘s College, Oxford University and a member of the Executive Advisory Board for the Centre for Personalised Medicine at Oxford University. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.

Andrew Hack

Partner, Bain Capital Life Sciences

Andrew A. F. Hack, M.D., Ph.D., is a Partner at Bain Capital Life Sciences which manages a series of private equity funds focused on investing in companies developing and commercializing transformative medicines, medical devices, diagnostics, and life sciences tools and services. Previously, he was chief financial officer of Editas Medicine, the first publicly-listed CRISPR gene editing company. Prior to that, he served as a portfolio manager at Millennium Management where he ran a healthcare hedge fund focused on investing in biotechnology, pharmaceutical, and life sciences companies. Earlier in his investment career, he was a securities analyst at a number of healthcare-focused hedge funds and investment banks in New York. He began his career in the biotechnology industry as Director of Life Sciences at Reify Corporation, a machine vision and machine learning-based drug discovery and technology company. Andrew currently serves as a member of the boards of directors of Alkeus Pharmaceuticals, Imperative Care, JenaValve Technology, and Swixx BioPharma. He has previously served on more than a dozen boards of directors, including Affinivax (acquired by GSK), Dynavax Technologies Corporation (NASDAQ: DVAX; acquired by Sanofi), Merida Biosciences, Mersana Therapeutics (NASDAQ: MRSN; acquired by Day One Biopharmaceuticals), and Nuvalent (NASDAQ: NUVL; acquired by GSK). Andrew received an A.B. in biology with special honors, an M.D., and a Ph.D. in molecular genetics and cell biology from the University of Chicago.

Pierre Jacquet

Vice Chairman, Global Healthcare Managing Director, L.E.K. Consulting

Pierre Jacquet is Vice Chairman, Global Healthcare Managing Director of L.E.K. Consulting. He has served in a variety of leadership roles for L.E.K., including the firm’s Global Leadership Team, the Americas Management Committee, and various partner operating committees since 2001. Dr. Jacquet has spent more than two decades focused on corporate strategy consulting, merger and acquisition advisory services, and value management, both domestically and internationally. A former physician, he worked with Genzyme in business development for Genzyme. During his medical career, he was a Fellow at the Washington Cancer Institute from 1993 to 1996, where he authored over 30 publications and presentations. Dr. Jacquet is a Director of Neurvati, a Blackstone company and Mereo Biopharma (Nasdaq: MREO). He previously served as a Director of Exact Sciences (Nasdaq: EXAS) and Osprey Pharmaceuticals. Dr. Jacquet earned a Master of Business Administration from the Darden Graduate School at the University of Virginia, was awarded a Doctor of Medicine with high distinction, and a Doctor of Philosophy in biomedical sciences from the University of Liège in Belgium.

Mathai Mammen

Chairman, CEO, & President, Parabilis Medicines

Mathai Mammen, M.D., Ph.D., is Chairman, CEO, and President of Parabilis Medicines, a biopharmaceutical company pioneering therapies for previously “undruggable” protein targets for patients with serious diseases. Under Mathai’s leadership, Parabilis has established a differentiated portfolio of potentially transformational medicines targeting disease-driving biology long considered out of reach, including zolucatetide (previously FOG-001), the first and only inhibitor of the elusive β-catenin:TCF interaction, and promising discovery-stage assets targeting ERG and allosteric ARON in prostate cancer – together reflecting the HeliconTM platform’s ability to repeatedly engage high-difficulty targets. Under Mathai’s leadership, Parabilis has established a differentiated portfolio of potentially transformational medicines targeting disease-driving biology long considered out of reach, including zolucatetide (previously FOG-001), the first and only inhibitor of the elusive β-catenin:TCF interaction, and promising discovery-stage assets targeting ERG and allosteric ARON in prostate cancer – together reflecting the Helicon platform’s ability to repeatedly engage high-difficulty targets. Previously, Mathai served as Global Head of R&D and a member of the Executive Committee at Johnson & Johnson. There, he led and evolved one of the world’s largest pharmaceutical R&D organizations and spearheaded the strategic integration of data science and AI across the portfolio. During his tenure, his team secured global approvals for nine medicines including Tremfya™, Darzalex Faspro™, Carvykti™, Tecvayli™, and Spravato™ and achieved an unprecedented 90% success rate in Phase 2 to Phase 3 transitions. He also oversaw 40+ acquisitions and licenses, , including the acquisition of Inlexzo™, along with 350+ strategic partnerships that expanded J&J’s portfolio and capabilities. Before J&J, Mathai was SVP at Merck, contributing to the development of Keytruda™ and the discovery of enlicitide, and earlier co-founded Theravance, Inc., where he led R&D toward five approved therapies including Breo™, Anoro™, and Trelegy™. In total, he has led the discovery/development of 19 approved medicines. He serves on the boards of Sandoz, Xaira, Kelonia, and GBH, and is an advisor to General Atlantic and Foresite Capital. He holds an M.D. from Harvard/MIT (HST) and a Ph.D. from Harvard University.

Giovanni Mariggi

Partner & Member of Co-Founding Team, Medicxi

Giovanni is a Partner at Medicxi and a member of the co-founding team. Prior to Medicxi, Giovanni was a Principal at Index Ventures for four years, having joined in 2012. He led Medicxi’s investment in Obseva and currently serves on the boards of a number of portfolio companies, including Vaderis, Gadeta and Aura Biosciences. Prior to joining Index, Giovanni was at Cancer Research UK's London Research Institute (now the Crick Institute) where he conducted research on vascular biology and angiogenesis, whilst also delivering competitive intelligence projects in oncology as an independent consultant to various biopharma. Giovanni received a BSc in Biochemistry from Imperial College London and a PhD in Biochemistry and Molecular Biology from University College London.

Dezső Mártha

Chief Operating Officer

Dr. Dezső Mártha is an experienced pharmaceutical executive and medical doctor with more than two decades of leadership experience across Central and Eastern Europe. As Chief Operations Officer at Swixx Biopharma, he oversees regional operations, strategic partnerships, organizational development, and the expansion of the company's commercial platform across more than 30 international markets. He joined Swixx Biopharma in 2019 after serving as Head of the Central and Eastern Europe region at Celgene. Prior to that, he spent 13 years in a variety of leadership roles at Bristol Myers Squibb, including alliance management responsibilities, building extensive expertise in commercial operations, market access, and strategic partnerships. Throughout his career, Dr. Mártha has played a key role in enabling access to innovative medicines and driving organizational growth across diverse and complex markets. He holds a medical degree and has dedicated his professional career to the pharmaceutical industry. In addition to his industry experience, he was involved in international anti-doping activities and served in leadership roles supporting the integrity of professional sports.

Mark C. McKenna

Chairman & CEO Mirador Therapeutics, Inc

Mark C. McKenna is the founder, Chairman, and CEO of Mirador Therapeutics, and a renowned biotech entrepreneur, executive, and director known for his exceptional leadership and visionary approach. Mirador is a next-generation precision medicine company focused on developing first-in-class or best-in-class precision medicines for immunology and inflammation. Launched in 2024, Mirador has raised over $650 million plus from leading life sciences investors and is based in San Diego, CA. Prior to Mirador, Mr. McKenna served as Chairman, President, and CEO of Prometheus Biosciences from 2019 until its acquisition by Merck for $10.8 billion in June 2023. Under his leadership, Prometheus raised over $1 billion in private and public financing, was recognized as the top-performing biotech IPO of 2021, and pioneered the first precision therapeutics clinical trial for immune-mediated diseases. This led to its acquisition by Merck, resulting in the largest buyout of company with a pre-Phase 3 asset to date. Prior to Prometheus Mr. McKenna was the President of Salix Pharmaceuticals and a corporate officer at Bausch + Lomb. There, he revitalized the gastroenterology business through strategic acquisitions and product launches, doubling revenue to over $2 billion and significantly enhancing operating margins. He also spent over a decade at Bausch + Lomb, where he was SVP and General Manager of the US Vision Care business. Mr. McKenna began his career at Johnson & Johnson, where he held several positions of increasing responsibility. He currently serves as the Chairman of Apogee Therapeutics, Inc. (Nasdaq: APGE) and is a board member of Spyre Therapeutics, Inc. (Nasdaq: SYRE) and New Amsterdam Pharma (Nasdaq: NAMS). In addition, Mr. McKenna is a Venture Partner at Arch and Senior Advisor to Fairmount Funds. Mr. McKenna holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton’s Fellows Program at the University of Pennsylvania School of Business. Mr. McKenna is passionate about solving big problems in medicine and is regularly featured on CNBC’s Mad Money and Bloomberg radio. In addition, Mr. Mckenna is a frequent speaker at the Longwood Healthcare Conference and other industry thought leader events. In 2023 he was selected as EY’s Entrepreneur of the year, being recognized for his contributions to advancement of entrepreneurship and science.

Amit Mehta

Chief Operating Officer & Chief Business Officer, Dren Bio

Amit Mehta joined Dren Bio in October 2023 and currently serves as our COO and CBO. Dr. Mehta most recently served as the VP and Head of Business Development at Genentech. In this role, Dr. Mehta was a core member of the Genentech Research and Early Development (gRED) Leadership Team, Research Review Committee, Early Stage Portfolio Committee and led a high-performing team that helped source and execute several strategic partnerships. During his 18-year tenure at Genentech, Dr. Mehta held roles of increasing responsibility that spanned process development, manufacturing, product strategy and business development. He led multiple teams over the years that made significant contributions to numerous early and late-stage programs, helped shape therapeutic area strategies and established vital external partnerships across technology platforms, personalized healthcare, and several therapeutic areas. Dr. Mehta received his Bachelor of Engineering in Chemical Engineering from Bangalore University and a PhD in Chemical Engineering from Pennsylvania State University.

George Simeon

Vice-President, Eli Lilly

George Simeon (99J) is a healthcare executive, entrepreneur, and board director with more than 30 years of global leadership experience across vaccines, biopharmaceuticals, medical devices, diagnostics, and healthcare technology. He has built and led healthcare organizations across North America, Europe, and Asia, with expertise in corporate strategy, capital formation, mergers and acquisitions, clinical development, market access, and corporate governance. He most recently served as Chief Executive Officer and Director of Curevo Vaccine, a clinicalstage biotechnology company developing next-generation vaccines. Under his leadership, Curevo raised more than $200 million from leading healthcare investors, advanced its shingles vaccine candidate from IND through successful Phase 2 development to Phase 3 readiness, and completed a strategic transaction resulting in the company's $1.5 billion acquisition by Eli Lilly. He also served as a Chairman of the Board and established an international Scientific and Regulatory Advisory Board comprising leading vaccine experts. George currently is NACD Certified in corporate governance. He holds an MBA from INSEAD, an MPH in Epidemiology and Health Economics from Yale University School of Medicine, and an MPhil from Bocconi University.

Moncef Slaoui

Chairman Curevo Vaccine

Dr Moncef Slaoui, a Moroccan Belgian and American scientist, holds a PhD in Immunology. He spent a long career in vaccine and medicine research and development during which he was involved in the development of several vaccines including the first ever vaccine against Malaria. In 2020 he was the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the Operation enabled the fastest ever development manufacturing and approval of COVID19 vaccines. He was Chairman of R&D at GSK where his career spanned almost 30 years. After retiring from GSK in 2017, he joined Medicxi ventures and since remained a dynamic force in life sciences, serving on the boards of several Biotechnology companies including Moderna and Vaxcyte (2017-2020). He currently chairs the boards of Altesa Arcturus and Curevo. In 2016, Dr Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world.

Otello Stampacchia

Managing Director, Omega Funds

Otello founded Omega Funds in 2003 and leads the firm’s investor relations and strategic initiatives. He is a member of the firm’s investment committee and is also heavily involved in a number of Omega’s therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory disorders. Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. Before AlpInvest, he was the portfolio manager of the Lombard Odier Immunology Fund, a $3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.

Stuart Swanson

Founder, Board Member and Head of Corporate Development

Co-Founder PharmaSwiss, formerly Head of Marketing at BMS CEE/Israel, GM Pfizer Russia and US Diplomat.

Nenad Tomasevic

Chief Executive Officer & Founder, Dren Bio

Nenad Tomasevic co-founded Dren Bio as CEO in May 2019 and has served on our board of directors since inception. Dr. Tomasevic most recently served as VP of Research for Allakos, a company he helped co-found after identifying the original opportunity for developing therapeutic antibodies against Siglec-8. During his time at Allakos, he was responsible for all research and nonclinical development functions. Prior to co-founding Allakos, Dr. Tomasevic previously held positions at KaloBios and Nuvelo, where his focus was on the development of therapeutic antibodies. Dr. Tomasevic began his career at Cytokinetics after receiving his PhD in protein chemistry from the University of Belgrade and completing his postdoctoral training at the National Institutes of Health (NIDDK, Genetics and Biochemistry Branch) in Bethesda, Maryland.

Stephen J. Ubl

President and Chief Executive Officer, Pharmaceutical Research and Manufacturers of America (PhRMA)

Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually – more than any other industry in America. Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. The New York Times writes, “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl. He is more conversant with the intricacies of health policy, and more adept at the politics." Previously, Ubl served as president and CEO of medical technology association AdvaMed, where he helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry. Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation). He is routinely recognized as one of Washington’s most effective advocates. Ubl has been recognized on Business Insider’s “DC Healthcare Power Players” and Modern Healthcare’s “100 Most Influential People in Healthcare.” He is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.

Jason Yang 杨建新

CEO, President of R&D and Executive Director of the Board, CStone Pharmaceuticals

A seasoned biopharma leader with over 30 years of experience driving end-to-end drug development—from discovery and translational research through clinical development and commercialization. Key Achievements: Successfully led the development and marketing of four novel oncology therapies in Greater China (sugemalimab, avapritinib, pralsetinib, ivosidenib) at CStone, secured EU/UK regulatory approval for sugemalimab in 2024, and established four commercial partnerships spanning over 60 countries. Built and advanced a global-facing, next-generation Pipeline 2.0, featuring innovative assets such as CS2009 (a potential first-in-class PD-1/VEGF/CTLA-4 trispecific antibody) and CS5001 (a best-in-class contender ROR1 ADC), alongside other promising ADC and autoimmune/inflammatory candidates. Established and led clinical development and operations functions as SVP/Head of Clinical Development at BeiGene, leading global development for four key oncology assets (PD-1, BTKi, PARPi, RAFi) and managing 10+ trials from first-in-human to registrational studies. Authored 80+ peer-reviewed publications and presentations in high-impact journals including JAMA, Nature Medicine, The Lancet Oncology, JCO, Nature Cancer, and Clinical Cancer Research, and holds 16 patents. Education: MD training from Hubei Medical College and Nanjing Medical University; PhD from UT Southwestern Medical Center under Nobel Laureates Michael S. Brown and Joseph L. Goldstein; Postdoctoral training at Harvard University with Stuart Schreiber.

CONFERENCE LOCATION

AURA Event Hall

Bleicherweg 5, Zürich
8001 Zürich

MONDAY DINNER

AURA Event Hall

Bleicherweg 5, Zürich
8001 Zürich

SUNDAY DINNER

Restaurant Seerose

Seestrasse 493, Zürich
8038 Zürich

REGISTRATION